TD Cowen analyst Yaron Werber maintained a Buy rating on Ionis Pharmaceuticals (IONS – Research Report) today and set a price target of ...

AstraZeneca AZN and Ionis Pharmaceuticals IONS announced that the Committee for Medicinal Products for Human Use (CHMP) has ...

AstraZeneca and Ionis are collaborating on the commercialisation of the drug following a December 2021 global agreement.

Ionis Pharmaceuticals (IONS) announced that Ionis’ and AstraZeneca’s (AZN) Wainzua has been recommended for approval by the ...

周二，TD Cowen重申Ionis Pharmaceuticals (NASDAQ:IONS)的买入评级和59.00美元的目标价，使该公司保持了稳定的前景。这一认可是基于该公司脊髓性肌萎缩症(SMA)治疗药物Spinraza的最新数据。在六个月时，Spinraza的高剂量相比之前研究中的安慰剂程序，在CHOP-INTEND评分（一种衡量SMA婴儿运动功能的指标）上显示出显著改善。 接受Spinr ...

周二，Laidlaw分析师重申了对Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)的买入评级和68.00美元的目标价，维持了对该公司的乐观展望。这一背书紧随该公司宣布在脊髓性肌萎缩症 (SMA)治疗中使用更高剂量nusinersen的研究取得积极结果之后。

On Thursday, Ionis Pharmaceuticals Inc (IONS) stock saw a decline, ending the day at $38.49 which represents a decrease of $-0.67 or -1.71% from the prior close of $39.16. The stock opened at $39.07 ...

While success is far from guaranteed in bio-land, with this week’s raising, Percheron has the horsepower to have a decent ...

Fire ideas will tend to be more adventurous and are designed for investors who can stomach a bit more volatility. Investments in a currency other than sterling are exposed to currency exchange ...

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...